Research-based content. This article is based on published research and publicly available pricing data. It is not medical advice. Do not start, stop, or change any medication without consulting a licensed healthcare professional. See sources below.
Denosumab (Prolia/Xgeva) in India — Biosimilar Price Comparison & Osteoporosis Treatment
Approximate Price Comparison (per month supply)
India
$60 – $150
US
$1,800 – $2,500
UK
$400 – $800
Prices are approximate and vary by dosage, brand, and pharmacy. Based on publicly available data.
Indian Manufacturers
The FDA approved Ponlimsi (denosumab-adet) on March 31, 2026 — adding another biosimilar to the osteoporosis treatment market. But even with biosimilar competition, US prices for denosumab remain orders of magnitude higher than in India.
A single Prolia injection in the US costs $1,800–$2,500. The same injection in India costs $60–$150.
Denosumab: The Numbers
Denosumab is a monoclonal antibody that blocks RANKL, a protein responsible for bone breakdown. It is used in two key settings:
- Osteoporosis (Prolia): One injection every 6 months — prevents fractures in postmenopausal women and high-risk men
- Cancer bone metastases (Xgeva): Monthly injection — prevents skeletal complications in cancer patients
| Indication | US Cost Per Injection | India Cost Per Injection | Annual US Cost | Annual India Cost |
|---|---|---|---|---|
| Osteoporosis (every 6 months) | $1,800 – $2,500 | $60 – $150 | $3,600 – $5,000 | $120 – $300 |
| Cancer (monthly) | $1,800 – $2,500 | $80 – $180 | $21,600 – $30,000 | $960 – $2,160 |
For cancer patients requiring monthly injections, the annual savings of switching to Indian biosimilar denosumab exceed $20,000.
The 2026 Biosimilar Landscape
The March 2026 approval of Ponlimsi is part of a broader trend:
- Prolia’s US patent exclusivity is eroding as multiple biosimilars enter the market
- India has had affordable denosumab biosimilars for years — the regulatory timeline in India is ahead of the US for biosimilar access
- US biosimilar pricing remains inflated compared to India due to PBM rebate structures and limited competition
Indian manufacturers supplying denosumab biosimilars:
| Manufacturer | Product | Export Status |
|---|---|---|
| Intas Pharmaceuticals | Denosumab biosimilar | WHO-GMP, exported to 70+ countries |
| Dr. Reddy’s | Denosumab biosimilar | FDA-approved facilities |
| Biocon | Biosimilar pipeline | Under development |
| Zydus Lifesciences | Denosumab biosimilar | CDSCO approved |
Medical Tourism Angle: The Osteoporosis Trip
For international patients on denosumab therapy, timing an India visit with their 6-monthly injection creates a compelling economic case:
Scenario: US patient on Prolia
| Cost Category | US (Stay Home) | India Medical Trip |
|---|---|---|
| Denosumab injection | $2,000 | $100 |
| DEXA bone density scan | $300 – $500 | $25 – $50 |
| Endocrinologist consult | $300 – $400 | $30 – $60 |
| Round-trip flight | — | $500 – $900 |
| Accommodation (3 nights) | — | $100 – $200 |
| Total | $2,600 – $2,900 | $755 – $1,310 |
Even including international flights and hotel, the India trip costs less than the US injection alone.
Cancer Patients: Bone Protection at Scale
For oncology patients with bone metastases requiring monthly Xgeva injections, the economics are even more dramatic:
12-month treatment cost comparison:
- US: $21,600 – $30,000
- India: $960 – $2,160
- Savings: $19,000 – $28,000 per year
Cancer patients traveling to India for chemotherapy, radiation, or targeted therapy automatically access denosumab at Indian prices as part of their treatment protocol. Hospitals like Tata Memorial, Rajiv Gandhi Cancer Institute, and HCG Cancer Centre include bone-protective therapy in their oncology packages.
Important Safety Considerations
Denosumab requires consistent use — stopping abruptly can cause a rebound effect with rapid bone loss and increased fracture risk. Medical tourists should:
- Plan continuity — ensure you have a supply or follow-up injection scheduled before your next India visit
- Coordinate with home doctors — share your Indian treatment records with your home country physician
- Never skip doses — the rebound bone loss risk is real and well-documented
- Monitor calcium and vitamin D — denosumab increases the risk of hypocalcemia; maintain supplementation as directed
Sources & References
- FDA Approval — Ponlimsi (denosumab-adet), RANKL Inhibitor Biosimilar, March 31, 2026
- Amgen — Prolia/Xgeva Prescribing Information, 2026
- International Osteoporosis Foundation — India burden of disease report
- CDSCO — Approved denosumab biosimilars in India, 2026
- Intas Pharmaceuticals — Biosimilar portfolio and regulatory filings
Frequently Asked Questions
How much does Denosumab (Prolia) cost in India vs the US?
Denosumab costs $1,800–$2,500 per injection in the US (administered every 6 months for osteoporosis). In India, biosimilar denosumab costs $60–$150 per injection. The FDA approved a new biosimilar, Ponlimsi (denosumab-adet), in March 2026, but even US biosimilar pricing remains 5-10x higher than Indian prices.
What is Ponlimsi and how does it affect pricing?
Ponlimsi (denosumab-adet) is a biosimilar to Prolia/Xgeva approved by the FDA on March 31, 2026. While it will lower US prices somewhat, the structural cost advantages of Indian pharmaceutical manufacturing mean that Indian-made denosumab biosimilars will remain significantly cheaper — approximately 90-95% less than US prices.
Can medical tourists get denosumab injections in India?
Yes. Denosumab injections are widely available at Indian hospitals and clinics. For osteoporosis patients, a single injection is administered every 6 months. International patients can receive their injection during a medical tourism visit and save $1,500+ compared to US pricing. Some patients time their India visits to coincide with their 6-monthly injection schedule.
Is Indian biosimilar denosumab as effective as Prolia?
Yes. Biosimilar denosumab must demonstrate equivalent clinical efficacy and safety to the reference product (Prolia) through rigorous comparative studies. Indian manufacturers like Intas and Dr. Reddy's produce denosumab in WHO-GMP compliant facilities that undergo regular regulatory inspection. Biosimilarity is a regulatory standard, not a marketing claim.
What is denosumab used for besides osteoporosis?
Beyond osteoporosis (Prolia indication), denosumab is used as Xgeva for preventing skeletal events in cancer patients with bone metastases, treating giant cell tumor of bone, and managing hypercalcemia of malignancy. Cancer patients traveling to India for treatment can access denosumab for bone protection at 90-95% lower cost than in the US.
Disclaimer: This content is for informational and educational purposes only, based on published research and publicly available data. It does not constitute medical advice, diagnosis, or treatment recommendations. Drug prices are approximate and vary by dosage, formulation, brand, and pharmacy. Always consult a qualified healthcare professional before making any decisions about medication. Fittour India is not a pharmacy, drug seller, or licensed medical provider.